Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has secured a second major managed Medicare agreement for its flagship fibromyalgia treatment, TONMYA (cyclobenzaprine HCl sublingual tablets), effective immediately. The agreement adds approximately 21 million Medicare lives, lifting total Medicare coverage for TONMYA to roughly 32 million lives—about 58% of the approximately 55 million Medicare beneficiaries in the United States. This development is significant because it substantially broadens access to the first new fibromyalgia treatment approved in more than 15 years, potentially improving outcomes for a patient population that has long faced limited therapeutic options.
Beyond Medicare, Tonix reported that total commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives, or 53% of the approximately 314 million total U.S. lives. This milestone reflects the company's rapid execution on its commercial strategy, which previously included agreements with two leading group purchasing organizations and one major managed Medicare plan. TONMYA is also covered by Medicaid in nearly all states, further solidifying its reimbursement footprint. For investors, these agreements signal growing revenue potential and validate Tonix's ability to navigate the complex U.S. payer landscape.
To support the expanded coverage, Tonix has fully activated approximately 50 new sales representatives, bringing its total sales force to 150 representatives. This field force expansion is critical for driving awareness and adoption among healthcare providers, especially given that fibromyalgia affects millions of Americans and often requires careful management. The increased sales presence should help Tonix capitalize on the broader payer access and accelerate TONMYA's uptake in a market where competition has been minimal.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet need. In addition to TONMYA, the company markets acute migraine products Zembrace SymTouch and Tosymra, and is advancing a pipeline that includes TNX-2900 for Prader-Willi syndrome, TNX-4800 for Lyme disease prophylaxis, and TNX-1500 for kidney transplant rejection prevention. The company is also conducting Phase 2 trials to evaluate TONMYA's potential in major depressive disorder and acute stress disorder. These efforts underscore Tonix's commitment to addressing serious conditions with innovative therapies.
For stakeholders seeking detailed information, the full press release is available at https://ibn.fm/Q8TKY, and ongoing updates can be found in the company's newsroom at https://ibn.fm/TNXP. The announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN. InvestorWire offers services such as editorial syndication to 5,000+ outlets and social media distribution to millions of followers. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
